Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Astellas Pharma Inc.. A complete text table follows the diagram.
Reported owners' profit was ¥147.6B after operating costs, financing, tax and attribution.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Revenue | 1 | 1030.1B | Reported interim top line |
| Operating profit | 2 | 199.4B | 19.4% operating margin |
| Operating costs & expenses | 2 | 830.7B | Arithmetic residual to reported operating profit |
| Profit before tax | 3 | 194.6B | Reported pretax result |
| Net non-operating cost | 3 | 4.8B | Arithmetic bridge to reported pretax profit |
| Net profit attributable to owners | 4 | 147.6B | Reported parent-company result |
| Tax, attribution & other | 4 | 47.0B | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Revenue | Operating profit | 199.4B |
| Revenue | Operating costs & expenses | 830.7B |
| Operating profit | Profit before tax | 194.6B |
| Operating profit | Net non-operating cost | 4.8B |
| Profit before tax | Net profit attributable to owners | 147.6B |
| Profit before tax | Tax, attribution & other | 47.0B |